Clinical bottom line
Intravenous valproate is an effective and generally well-tolerated option for early management of status epilepticus (SE) in the emergency department, particularly as a second-line agent after benzodiazepines. Evidence supports its use in both adult and pediatric populations, with favorable safety profiles and comparable efficacy to traditional agents such as phenytoin. However, its role as a first-line therapy remains investigational, and more high-quality randomized controlled trials are needed to define optimal timing, dosing, and patient selection (Prasad et al., 2014; Peters et al., 2005; Waterhouse et al., 2003).
What the evidence shows
Prasad et al. (2014) conducted a Cochrane systematic review evaluating anticonvulsant therapies for SE, highlighting that intravenous valproate is effective in terminating seizures with fewer adverse effects compared to phenytoin and phenobarbital. The review noted valproate’s rapid onset and favorable tolerability, making it a valuable option after benzodiazepine failure.
Peters et al. (2005) reported on 102 adult patients treated with intravenous valproate for seizure emergencies, including SE, demonstrating seizure cessation in approximately 70% of cases with minimal serious adverse events. This observational study supports valproate’s safety and efficacy in urgent settings.
Waterhouse et al. (2003) reviewed intravenous valproate use in pediatric SE, finding it to be a promising alternative with good seizure control and a low incidence of side effects, suggesting utility across age groups.
Van Paesschen et al. (2013) described a protocol combining lorazepam and levetiracetam followed by intravenous valproate in nonconvulsive SE, indicating potential benefits of multimodal early therapy incorporating valproate.
Grover et al. (2016) and Verrotti et al. (2017) provide expert commentary on evolving SE management, recognizing valproate as an important addition to the therapeutic armamentarium, especially in refractory cases.
Caveats and uncertainty
Most evidence for intravenous valproate derives from observational studies or small trials; large randomized controlled trials comparing valproate with other second-line agents remain limited.
Optimal dosing regimens and timing relative to benzodiazepines are not fully standardized.
Valproate’s use is contraindicated in certain populations (e.g., severe hepatic impairment, mitochondrial disorders), requiring careful patient selection.
Long-term outcomes and impact on functional recovery after SE treated with valproate need further study.
Potential drug interactions and monitoring requirements should be considered in polypharmacy contexts common in emergency settings.
How this may change practice
Emergency clinicians may consider intravenous valproate as a preferred second-line agent after benzodiazepines for SE, balancing efficacy and safety.
Protocols incorporating valproate earlier in SE management could reduce reliance on phenytoin or phenobarbital, potentially improving tolerability.
Multimodal approaches combining valproate with other anticonvulsants may optimize seizure control, particularly in nonconvulsive SE.
Increased familiarity with valproate’s pharmacology and contraindications will enhance safe implementation.
Future guidelines may increasingly endorse valproate based on accumulating evidence, pending results of ongoing trials.